Pertaining to the circulating information about some particular drugs which mentioned the prices and types, the Ministry of Health clarified in a statement the prices of the supply of some types of medicines, including Eculizumab (Soliris) 300mg and Vimizim. According to officials, all the mentioned drugs had been subject to approvals from the regulatory authorities, based on the frameworks regulating contracting procedures.
The ministry indicated that the number mentioned in the circulating document refers to the class of the drug that has been approved, in which the mentioned number, one – for example, refers to the brand, not the quantity of drug packages, which are specified in a separate contract.
In addition, the quantity of supply specified in the contract of Eculizumab (Soliris) 300 mg is 800 injections, not the number of “one package” as claimed, and that the quantity of the supply specified in the contract of Vimizim drug is 4000 injections, not the number of “one package” as claimed. Moreover, the special prices for the aforementioned medicines are equivalent to international, as well as, regional prices.
The ministry reiterated its legal right on anyone who circulated incorrect and unverifiable information, as well as, questioned the qualifications and challenged colleagues in the profession. It is also keen on abiding by laws regulating its contracts, and appeals to those who have supporting documents to back up their claims and approach relevant authorities.
Read Today's News TODAY... on our Telegram Channel click here to join and receive all the latest updates t.me/thetimeskuwait
